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Introduction and Aims The dramatic increase in pharmaceutical opioid (PO) use in high‐income countries
is a growing public health concern. Stigma and social support are important as they may influence treatment
uptake and outcomes, yet few studies exist regarding perceived stigma and social support among people with
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iatrogenic and non‐iatrogenic causes; (ii) document perceived stigma and its correlates in people in treatment
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female. Two in five met the criteria for iatrogenic dependence (n = 41, 38%), with iatrogenic dependence
associated with chronic pain, and no history of injection or heroin use. One quarter of study subjects reported
past month unsanctioned opioid use (n = 25, 23%). Being married/de facto or female was associated with
higher levels of perceived stigma. Unsanctioned opioid use, iatrogenic dependence and mental health
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Abstract 
Introduction: The dramatic increase in pharmaceutical opioid (PO) use in high-income 
countries is a growing public health concern. Stigma and social support are important as they 
may influence treatment uptake and outcomes, yet few studies exist regarding perceived 
stigma and social support among people with PO dependence. 
Aims: To: (1) compare characteristics of those with PO dependence from iatrogenic and non-
iatrogenic causes; (2) document perceived stigma and its correlates in people in treatment for 
PO dependence; (3) examine correlates of social support in people in treatment for PO 
dependence. 
 
Methods: Prospective cohort study (n = 108) of PO dependent people referred from 
treatment services. Telephone interviews were conducted at baseline, 3-, 12- and 24-months. 
Multivariate linear regression was used to examine correlations. 
Results: Mean age was 41 (SD = 10.5). Half (n = 56, 52%) were female. Two in five met the 
criteria for iatrogenic dependence (n = 41, 38%), with iatrogenic dependence associated with 
chronic pain, and no history of injection or heroin use. One quarter reported past month 
unsanctioned opioid use (n = 25, 23%). Being married/de facto or female was associated with 
higher levels of perceived stigma. Unsanctioned opioid use, iatrogenic dependence and 
mental health conditions were associated with lower social support.  
 
Conclusions: Stigma affects all people in treatment. Those who are married/de facto and 
female may benefit from interventions to address stigma. The association of low social 
support with poorer mental health and ongoing substance use may indicate that treatment 
could focus more on this area. 
 
Keywords 
Analgesics, Opioid; Social Stigma; Social Support; Opioid-Related Disorders; Opioid 
Substitution Treatment.  
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Introduction 
Globally, pharmaceutical opioid (PO) utilisation has increased dramatically [1]. In Australia, 
PO dispensing where scripts were subsidised by the government rose from 500 000 episodes 
in 1992, to 7.5 million in 2012 [2]. This increase is largely attributed to chronic pain 
treatment, despite little evidence for long-term effectiveness [3]. Alongside growing use, 
there are rising concerns regarding dependence, aberrant behaviour and overdose [4]. In 
Australia, accidental deaths due to any opioid increased by 76% between 2002 and 2011 [2]. 
In both Australia and the US, PO-related mortality now exceeds heroin-related mortality [5, 
6], with strong correlations between PO availability and related harms including mortality [7, 
8]. 
Demand for medication-assisted (methadone or buprenorphine) opioid dependence treatment 
where a PO is the primary drug of concern is rising [9]. However, most treatment is informed 
by research where participants are dependent on heroin, and less is known about those who 
use PO. Although medication assisted treatments for opioid dependence are effective [10-12], 
to optimise treatment for people who are dependent on PO, it is critical to understand factors 
that may facilitate or deter treatment entry and support positive treatment outcomes. This is 
particularly timely in Australia, where changes in availability of over-the-counter (OTC) 
opioids in early 2018 [13] may contribute to treatment demand. 
In the treatment of heroin dependence, greater social support is associated with better 
outcomes, such as earlier treatment-seeking [14], less heroin and other drug use [15-17], and 
improved mental health [15, 16]. Enhancing medication-assisted treatment with social 
support services like counselling, psychiatric care and family therapy also results in further 
decreases in opioid use [18]. However, there have been no studies examining the impact of 
social support on treatment outcomes in people who are dependent on PO.  
In addition to poor social support, stigma is likely to be an important barrier to treatment 
uptake and engagement in people dependent on PO [19]. Qualitative interviews with people 
who used OTC codeine found participants often referred to themselves as being ‘addicted’, 
and feeling “dirty and guilty,” with dependence often hidden from family and friends [20]. 
They also held stigmatising attitudes towards those who used heroin, with employment, 
education and appearance listed as reasons why people who used codeine were more 
‘respectable’. Another study of people in treatment for OTC codeine dependence found there 
were perceptions that medication-assisted treatments for opioid dependence were for ‘drug 
users’, namely heroin, and so were for ‘other people’, thus separating themselves from illicit 
opioid users [19].  
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Stigma may also act as a barrier to pain relief, for example those dependent on opioids who 
request further pain relief may be seen as drug-seeking by physicians, leading to poor 
communication and under-treatment [21]. Additionally, those engaged in community 
pharmacy medication-assisted opioid dependence treatment may be subjected to suspicion 
and patronisation [22, 23]. A study of people who used medications only as prescribed found 
the majority of participants believed that ‘normal’ people shouldn’t have to be exposed to 
‘drug-takers’ in the pharmacy [24]. These experiences suggest that stigma may pose an 
important barrier to treatment engagement for opioid dependent people, however this is not 
well researched in people dependent on PO. 
Although social support has been more commonly examined, most research on both stigma 
and social support concerns only illicit substances, leaving large gaps in the literature 
regarding PO dependence. This study utilises data from a cohort study conducted over two 
years with people in treatment for PO dependence. It examines perceived stigma and social 
support, which are modifiable factors that may improve treatment entry and outcomes for this 
emerging population. The aims of this study are: 
1. To compare characteristics of those with PO dependence from iatrogenic and non-
iatrogenic causes. 
2. To document perceived stigma and its correlates in people in treatment for PO 
dependence. 
3. To examine correlates of social support in people in treatment for PO dependence. 
 
Methods 
 
This study utilises baseline, 3-, 12- and 24-month follow-up data collected from a cohort of 
people in treatment for PO dependence. Ethics approval was obtained from Royal Prince 
Alfred Hospital Human Research Ethics Committee (HREC), and HRECs for the six Local 
Health Districts. 
 
Participants 
This study represents one component of a larger study [25]. There were 108 participants 
recruited for the parent study via healthcare provider referral or advertisements in drug 
treatment centres within New South Wales. Eligibility criteria included those who had 
entered treatment for PO dependence, and who were competent in English. Interviews were 
	   5	  
conducted via telephone at baseline, 3-, 12- and 24 months. Baseline interviews ranged from 
45 minutes to 1.5 hours in duration. Subsequent interviews ranged from 30 minutes to 1 hour. 
Participants were reimbursed $40 after each interview.  
 
Measures 
Demographic Measures 
Age and gender were collected. Education level was categorised into ‘completed year 10 or 
less’, ‘completed year 12/TAFE/technical college’ and ‘completed university/college’. 
Employment was dichotomised into ‘employed/student’ and ‘not employed’ to retain power 
for analyses. Marital status was dichotomised into ‘married/de facto’ and ‘not married’. 
Participants were asked who they currently lived with, which was dichotomised into ‘living 
alone’ and ‘living with others’. 
 
Physical Health 
Current health rating was determined using one item from the SF-12 Health Survey [26]: “In 
general, would you say your health is….?”. This was dichotomised into ‘excellent/very 
good/good’ and ‘fair/poor’. Participants were also asked about problematic arthritis or 
rheumatism, chronic back or neck problems, frequent or severe headaches, visceral pain, 
generalised pain and other chronic pain conditions in the past 12 months. This was 
dichotomised into ‘current chronic pain’ or ‘no current chronic pain’. 
 
Opioid Use History 
Participants were asked about their current treatment length, and which pharmaceutical 
opioid led them to treatment. ‘Primary opioid of concern’ was then dichotomised into ‘strong 
opioids’ (schedule 8: morphine, oxycodone, methadone, buprenorphine, fentanyl, 
hydromorphone) or ‘weak opioids’ (schedule 3 or 4: codeine, tramadol). Participants were 
asked about their first source (“When you first started to have a problem with taking more 
opioid analgesics than prescribed or misusing opioid analgesics, what was your first 
source?”) and reason for opioid use (“what was the major reason you first used opioid 
analgesics?”). They were classified as having ‘iatrogenic dependence’ if their first opioids of 
concern were prescribed by a doctor for a legitimate medical reason.  
Past month medical and illicit opioid use was reported, and ‘unsanctioned opioid use in the 
past month’ was defined as non-medical use of any opioids, or use of heroin. Participants 
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were also asked, “have you ever used heroin?” and whether they had ever injected heroin, 
non-medicinal or non-prescribed opioids, methamphetamine, cocaine, ecstasy, cannabis, 
alcohol, tobacco, non-medicinal or non-prescribed benzodiazepines, hallucinogens or other. 
This was dichotomised into ‘have injected’ and ‘have never injected’.  
 
Mental Health 
Participants were asked to report if they had been diagnosed with a range of mental health 
conditions including depression, dysthymia, anxiety/panic disorder, bipolar/manic depressive 
disorder, obsessive-compulsive disorder, schizophrenia, psychosis, ADD/ADHD and 
personality disorder, and to report if these had been problematic in the past 12 months. 
Additionally a cut-off score of ≥ 3 on the Primary Care PTSD screen [27] was considered 
indicative of post-traumatic stress disorder. All conditions were summed to create a ‘mental 
health conditions in past 12 months’ variable.  
 
Perceived Stigma of Addiction Scale (PSAS) 
This scale contains 8 items scored between 1 (strongly disagree) and 4 (strongly agree) 
(Appendix A) [28]. Participants were asked to complete this survey in the 24-month 
interview. Questions 1, 2, 3, 4, 6 and 8 were reverse scored. Item scores were combined to 
obtain a total score between 8 and 32, where higher scores indicated more perceived stigma. 
This scale has been found to display good convergent and discriminant validity, and adequate 
internal consistency reliability (α = .73) [28]. It has previously been used in studies 
concerning opioid dependence [29] and substance use more generally [30]. 
 
Medical Outcomes Study (MOS) Social Support Survey 
This survey contains items that ask how often support is available and is scored between 1 
(none of the time) and 5 (all of the time) [31]. It contains 19 items sorted into 5 scales: (1) An 
emotional/informational subscale, (2) a positive interaction subscale, (3) a tangible support 
subscale, (4) an affectionate support subscale and (5) a combined overall social support scale 
[31]. Total scores are calculated with a provided formula [32], and range from 0 to 100, 
where higher scores indicate more support. For the purpose of this study we used only the 
items that formed the emotional/informational support (EIS) and positive interaction support 
(PIS) subscales, and the overall support (OS) score (the sum of all questions) (Appendix B). 
This survey has been found to display high convergent and discriminant validity, and high 
internal consistency reliability (α = .97) [31]. It has been used in previous research with 
	   7	  
people prescribed PO for chronic non-cancer pain [33], and those in medication-assisted 
treatment for any opioid use [34]. 
 
Analysis 
 
Cronbach’s alpha was calculated for stigma and social support scales. The internal 
consistency reliability of the PSAS was acceptable (α = .744), and for the MOS social 
support survey was excellent (α = .965). 
Analyses were conducted using SPSS version 22.0. Chi-square tests, Independent t-tests and 
Mann-Whitney U tests were used to examine baseline differences between those who 
initiated opioid use for iatrogenic and non-iatrogenic reasons. Bivariate correlates of stigma 
and social support were determined using Independent t-tests, ANOVA and Pearson’s 
product-moment correlations where variables were normally distributed. Where they were 
not normally distributed, Mann-Whitney U tests, Kruskal-Wallis tests and Spearman’s 
correlations were used. Multivariate linear regression was then used to examine significant 
bivariate associations after controlling for age, gender and other variables significant at the 
bivariate level. Generalised estimating equations (GEE) were used to determine changes in 
overall social support over the 2-year study period.  
To determine effects of attrition on the data, participants who completed all four interviews 
(n = 85), and those who completed between one and three interviews (n = 23) were 
compared. There were no significant differences (Appendix D). 
There was a large amount of missing stigma data (missing n = 21/87), as a total score could 
not be calculated with a single question unanswered. As the scale includes no instructions for 
missing data, we used multiple imputation with fully conditional specification to impute 
missing item-level data to maintain power for our analysis. As 24% of the data was missing, 
20 imputations were run [35]. Age, sex, education, employment, living situation, marital 
status, health rating, iatrogenic dependence, primary drug of concern, heroin use history, 
injection history, OS, EIS, PIS, and completed stigma questions were used as predictors. 
Analyses were performed with both complete-case data and imputed data, with correlates 
deemed dependable if they were significant with imputed data, and showed an association in 
the same direction with complete-case data.  
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 Results 
Baseline characteristics according to whether initiation of PO use was iatrogenic 
or non-iatrogenic 
 
The mean age was 41 years (SD = 10.54). Half (n = 56, 52%) were female and one third (n = 
32, 30%) reported current employment/study (Table 1). One third (n = 37, 34%) were 
married/de facto, and most (n = 73, 68%) were living with others. Forty-one participants 
(38%) reported current chronic pain, and 38% (n = 41) were classified as having iatrogenic 
dependence. Just over half (n = 61, 57%) had ever used heroin, and a quarter had used 
unsanctioned opioids within the past month (n = 25, 23%).  
Iatrogenic dependence was associated with a higher prevalence of chronic pain, compared to 
non-iatrogenic dependence (56% vs. 27%, OR 3.48, 95% CI [1.53, 7.90]). It was also 
associated with a lower prevalence of lifetime heroin use (40% vs. 67%, OR 0.31, 95% CI 
[0.14, 0.70]), and injection of any drug (42% vs. 69%, OR 0.32, 95% CI [0.14, 0.73]) (Table 
1). 
 
Perceived Stigma  
Participants reported that they perceived stigma in all domains (including childcare, 
employment and personal interaction), scoring a mean of 23.30 out of a possible range of 8 to 
32 (Table 1). Perceptions of stigma were greatest around the prospect of caring for children 
and gaining employment, and least around friendship and dating, though scores still indicated 
stigma in these domains (Figure 1) (Appendix A).  
 
Bivariate analysis identified that being married or in a de facto relationship and being female 
were associated with higher levels of overall perceived stigma (Table 2). Both genders 
experienced stigma in similar domains, but females consistently reported more stigma for 
each question, though the differences were not significant in any individual domain (Figure 
1). After controlling for age and gender in a multivariate linear regression model, only marital 
status remained significantly associated with higher levels of overall perceived stigma (B = 
2.00, 95% CI [0.46, 3.54] p = .011) (results not presented). 
 
Social Support  
The median overall support (OS) score was 54.17 (IQR = 47.40, scale 0-100), median 
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emotional/informational support (EIS) score was 62.50 (IQR = 43.75) and median positive 
interaction support (PIS) score was 58.33 (IQR = 50.00). Initially associations of social 
support were to be examined longitudinally, however no significant effect of time on OS was 
identified (i.e. social support did not change over time) (Appendix C), so cross sectional 
analyses at Baseline are presented, providing the largest sample size to explore associations.  
 
At the bivariate level, unsanctioned opioid use and the number of mental health conditions 
were associated with lower levels of OS, EIS and PIS (Table 4). Iatrogenic dependence was 
associated with lower OS and EIS, but did not reach significance for PIS. Length of current 
treatment episode was negatively associated only with PIS. Living with other people and 
being married or in a de facto relationship was associated with higher OS, EIS and PIS. Being 
employed or studying correlated positively with only PIS. 
 
Controlling for age, gender and variables significant at the bivariate level, unsanctioned 
opioid use in the past month remained significant for lower levels of OS (B = -19.36, 95% CI 
[-31.10, -7.31] p = .002), EIS (B = -21.93, 95% CI [-34.26, -9.60] p = .001) and PIS (B = -
14.71, 95% CI [-28.25, -1.16] p = .034). Mental health conditions remained significantly 
associated with lower OS (B = -3.83, 95% CI [-6.77, -0.89] p = .011), EIS (B = -3.44, 95% CI 
[-6.46, -0.43] p = .026) and PIS (B = -3.73, 95% CI [-7.11, -0.34] p = .031). Iatrogenic 
dependence remained significantly associated with lower OS (B = -12.62, 95% CI [-22.73, -
2.50] p = .015) and EIS (B = -12.93, 95% CI [-23.21, -2.65] p = .014) (results not presented). 
 
Discussion 
 
This is the first study to systematically explore perceived stigma and social support in a 
cohort of people in treatment for PO dependence. Participants reported considerable levels of 
perceived stigma in all domains examined, with the highest levels relating to childcare and 
employment. One possible explanation for this is great levels of perceived responsibility, 
reflecting a societal protectiveness of children and condemnation of exposing them to risk-
taking behaviour, as well as the importance of performing jobs safely and effectively. 
Unsanctioned opioid use, mental health conditions and dependence from iatrogenic opioid 
use were associated with lower levels of social support. This suggests that a greater focus on 
increasing social support in treatment may be warranted. 
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Being married or in a de facto relationship was the strongest independent predictor of higher 
perceived stigma. This finding may appear counterintuitive, as the individual scale question 
“most people would be willing to date someone who has been in treatment for substance 
use”, was scored lowest by the cohort, indicating they saw relationships as the least 
stigmatising scenario. This discrepancy may highlight complex interactions between stigma 
and relationships. One strategy to address stigma in married people may be involvement of 
drug-free partners in treatment, in an attempt to expose them to reasons behind their partner’s 
drug use, and provide education that dependence is a medical condition that may be treated 
[36].  
High levels of perceived stigma may act as a barrier to treatment engagement. National drug 
control strategies often revolve around strict law enforcement and depictions of drug-related 
harm in the media, attempting to discourage people from drug use. However, depictions of 
negative images related to drug use increases social stigma, whilst decreasing public support 
for effective treatment in favour of punishment [37]. Importantly, shame amongst people in 
drug treatment has been linked with relapse [38]. To target stigma at a societal level, it may 
be useful to depict successfully treated drug dependence [37], and implement community 
awareness campaigns and education programs aimed at professionals including police, 
doctors and counsellors [39]. 
Several factors including heroin use history, injection history and mental health problems 
were not associated with differences in perceived stigma. These findings are of importance, 
as Australian and UK studies of people who used OTC codeine demonstrated stigmatising 
attitudes towards people who used heroin or injected drugs [19, 20]. Our finding of no 
association between heroin use or injection with higher levels of stigma suggest that the way 
people in treatment for PO use perceive stigma towards themselves may be different to how 
they project it on others.  
Unsanctioned opioid use in the past month, mental health conditions and iatrogenic 
dependence were independently associated with lower levels of social support. Studies have 
shown that higher levels of social support [15], and specific social network interventions [40] 
may lead to better treatment outcomes in opioid dependent people. Our results indicate that 
those with unsanctioned opioid use, mental health conditions and iatrogenic dependence may 
benefit most from interventions to increase social support, given the positive associations 
between social support and treatment outcomes. Future work examining social network 
involvement in all facets of treatment, for example pain management, mental health 
counselling and opioid treatment, could test if interventions to improve social support may 
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benefit those with PO dependence.  
Our findings of lower social support in those with iatrogenic dependence are in keeping with 
previous studies of social support in chronic pain. In qualitative interviews of people with 
chronic pain, only two out of thirteen participants reported that they had someone they could 
talk to in depth about their experience [41]. This is important, as social support may have 
beneficial effects on morbidity, mortality and quality of life in chronic pain populations [42-
44], in addition to potential positive effects on substance dependence treatment outcomes [15, 
40]. 
The results of this study indicate that there was no change in social support over time. This 
may have been due to the social support measure lacking sensitivity in this population. The 
sensitivity has not been measured in PO dependent people. However, the scale has previously 
detected significant longitudinal changes in other studies [45]. Only those who had already 
entered treatment were recruited, but it may be the case that greater changes in social support 
are observed alongside uptake of treatment, which may not have been captured due to this 
eligibility criterion. Additionally, changes in social support after entering treatment may take 
longer to observe than the study length of two years. As such, future work may include a 
longer follow-up period. Another explanation for these findings may relate to the treatment 
itself. As standard treatment practices generally do not involve family, friends or partners, 
changes in social support may not be expected. The finding that social support did not appear 
to change on its own indicates that social interventions may be required to increase support, 
in an attempt to improve treatment outcomes. 
Some limitations should be considered in interpreting these findings. We recruited 
participants already engaged in treatment through advertisements and healthcare provider 
referral. This method may have excluded those who felt most stigmatised, who may not have 
entered treatment or agreed to be referred for the study. All data was obtained via self-report, 
which is inherently subject to reporting bias, however self-report studies are generally 
considered reliable in the context of substance abuse [46]. The use of multiple imputation to 
obtain complete stigma data introduced inherent limitations to the final results. These were 
minimised through the number of imputations, and running analyses with both case-complete 
and imputed data. Additionally as the stigma scale was only included in the 24-month 
interview, changes in stigma over time could not be examined. Although of modest sample 
size, this study is the first of its kind, lending importance to its findings. There was a good 
retention rate at the 2-year interview (80%) and there were no significant differences between 
those who completed one to three interviews, and those who completed all four interviews, 
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suggesting attrition may not have influenced results. 
 
Conclusions 
 
This study represents the first in Australia to examine perceived stigma and social support in 
a cohort of people in treatment for PO dependence, an area that has been neglected in the 
literature. Overall, the findings of this study identify that women and people in a relationship 
may be most affected by stigma, whilst those who exhibit unsanctioned opioid use, mental 
health conditions and iatrogenic dependence may benefit most from social support 
interventions. Future studies might build on these findings, aiming to address stigma and 
social support to improve treatment uptake and outcomes in people dependent on PO.  
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